The LuMIERE study a prospective phase I/II study in patients with advanced or metastatic solid tumors evaluating the safety, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of [177Lu]Lu-FAP-2286 [34]. Here, FAP is linked to neoplasm.